Vitaeris
CSL Behring is a global biotherapeutics leader dedicated to improving human health by discovering, developing, and delivering innovative therapies across various medical fields including immunology, hematology, cardiovascular, respiratory, and transplant. The company employs advanced technologies such as plasma fractionation, recombinant protein technology, and cell and gene therapy to address unmet medical needs and enhance patient lives. With a strong commitment to patient-centric care, CSL Behring develops treatments for rare and serious diseases, emphasizing transparency, collaboration, and innovation.
Industries
Nr. of Employees
small (1-50)
Vitaeris
Vancouver, British Columbia, Canada, North America
Products
Plasma‑derived therapeutics (immunoglobulins, albumin, clotting factors)
Therapeutic products derived from human plasma used to treat immunodeficiency, bleeding and other plasma-responsive conditions.
Seasonal and pandemic vaccines
Vaccines for seasonal influenza and pandemic preparedness produced on established manufacturing platforms.
Antivenoms and specialty vaccines
Development and deployment of antivenoms and regionally relevant specialty vaccines informed by case studies and field programs.
Patient support and access programs
Programs to support patient access to therapies including managed access pathways and financial assistance mechanisms.
Excipient-grade human serum albumin and plasma-derived manufacturing inputs
Human serum albumin and plasma-derived materials (fibrinogen, thrombin) available for purchase for use as excipients or manufacturing inputs.
Plasma‑derived therapeutics (immunoglobulins, albumin, clotting factors)
Therapeutic products derived from human plasma used to treat immunodeficiency, bleeding and other plasma-responsive conditions.
Seasonal and pandemic vaccines
Vaccines for seasonal influenza and pandemic preparedness produced on established manufacturing platforms.
Antivenoms and specialty vaccines
Development and deployment of antivenoms and regionally relevant specialty vaccines informed by case studies and field programs.
Patient support and access programs
Programs to support patient access to therapies including managed access pathways and financial assistance mechanisms.
Excipient-grade human serum albumin and plasma-derived manufacturing inputs
Human serum albumin and plasma-derived materials (fibrinogen, thrombin) available for purchase for use as excipients or manufacturing inputs.
Services
Clinical trial management and participant engagement
Design and conduct of clinical studies, participant recruitment guidance and research practice support for clinical trial sites.
Research funding and investigator-initiated study support
Grant programs and support pathways for investigator-initiated studies and external research collaborations.
Plasma collection and donor center operations
Operation and management of a network of plasma collection centers and donor engagement services to support biologics manufacturing inputs; vertically integrated sourcing used to supply downstream manufacturing.
Pharmacovigilance and adverse event reporting
Safety monitoring services including adverse event intake, case management and regulatory reporting channels.
Excipient-grade human serum albumin and plasma-derived material supply
Commercial provision of human serum albumin and plasma-derived materials (fibrinogen, thrombin) intended for use as excipients or manufacturing inputs by pharmaceutical and contract manufacturers.
Clinical trial management and participant engagement
Design and conduct of clinical studies, participant recruitment guidance and research practice support for clinical trial sites.
Research funding and investigator-initiated study support
Grant programs and support pathways for investigator-initiated studies and external research collaborations.
Plasma collection and donor center operations
Operation and management of a network of plasma collection centers and donor engagement services to support biologics manufacturing inputs; vertically integrated sourcing used to supply downstream manufacturing.
Pharmacovigilance and adverse event reporting
Safety monitoring services including adverse event intake, case management and regulatory reporting channels.
Excipient-grade human serum albumin and plasma-derived material supply
Commercial provision of human serum albumin and plasma-derived materials (fibrinogen, thrombin) intended for use as excipients or manufacturing inputs by pharmaceutical and contract manufacturers.
Expertise Areas
- Plasma-derived biologics manufacturing
- Vaccine development and manufacturing
- Clinical trial management and patient engagement
- Cell and gene therapy research
Key Technologies
- Plasma fractionation
- Recombinant protein expression and production
- Protein purification and concentration
- High-throughput sterile fill–finish automation